What is Acute Myeloid Leukemia Therapeutics Market Scope?
Acute myeloid leukemia is the second most common type (after acute lymphoblastic leukemia) of leukemia diagnosed in infants. Approximately 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely related to age. About 90% of acute myeloid leukemia are diagnosed in middle age. The incidence rate of acute myeloid leukemia is high in men and women over 50 years of age. The Acute Myeloid Leukemia Market is divided into two types namely, acute myeloid leukemia in childhood and acute myeloid leukemia in adults. Acute myeloid leukemia (AML) is a type of blood cancer that usually affects white blood cells (WBC). However, it can also occur in other types of blood-forming cells. AML is the rapid production of abnormal WBCs that accumulate in the bone marrow and affect the production of normal blood cells. AML: Acute myeloid leukemia is a serious disease and the most common leukemia in adults. According to a report by the American Cancer Society, the median age at first diagnosing AML is 64 years. With a few days without treatment, AML develops rapidly, and within a few weeks, the patient becomes seriously ill. Because of its rapid onset and harshness in nature, there is no staging system for acute myeloid leukemia (AML). The treatment of acute myeloid leukemia (AML) has changed over the past 4 decades. The drug approval process is difficult for AML (many drugs have not been approved by the USFDA, such as Laromustine, Dacogen, and Tipitarnib). Efforts have been made to introduce new therapies to the AML market.
The Acute Myeloid Leukemia Therapeutics market study is being classified by Type (Pipeline Drugs, Chemotherapy Drugs and Chemotherapy Regimens), by Application (Hospitals, Clinics and Home Care) and major geographies with country level break-up.
The companies are exploring the market by adopting expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA predicts that Players from United States will contribute to the maximum growth of Global Acute Myeloid Leukemia Therapeutics market throughout the predicted period.
Ambit Biosciences Corporation (United States), Celgene Corporation (United States), Bristol-Myers Squibb (United States), Novartis International AG (Switzerland), GlaxoSmithKline (United Kingdom), Cephalon Inc. (United States), Clavis Pharma ASA (United States), Eisai Co. Ltd. (Japan), Genzyme Corporation (United States), Sunesis Pharmaceuticals Inc. (United States) and Abbvie Inc. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Astellas Pharma Inc. (Japan) and CTI Biopharma Corp (United States).
Analyst at AMA have segmented the market study of Global Acute Myeloid Leukemia Therapeutics market by Type, Application and Region.
On the basis of geography, the market of Acute Myeloid Leukemia Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
In, August 2017 the U.S. Food and Drug Administration today approved Idhifa (enasidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML. Idhifa is a targeted therapy that fills an unmet need for patients with relapsed or refractory AML who have an IDH2 mutation. The use of Idhifa was associated with a complete remission in some patients and a reduction in the need for both red cell and platelet transfusions.
Influencing Market Trend
- Increasing Level of Carcinogens in the Environment
- The Availability of the Treatment and Launch of Newer Drugs
- Rise in Awareness about the Leukemia Treatment
- Increasing Number of Cancer Hospitals
- Growing Population of Acute Myeloid Leukemia
- A Rise in Changing Lifestyle and Family History
- Increasing Inclination towards Therapies Such As Targeted Therapies Resulting In Low Collateral Damage and Stronger Efficacy
- Rise in Advanced Healthcare Infrastructure and Need for Targeted Therapies
- An Upsurge in Huge Investment for the Development of Pipeline Drugs
- Increasing Number of Stem Cell Transplant
- Lack of Standardized Treatment
Key Target AudienceProviders of Acute Myeloid Leukemia Therapeutics, Raw Material Suppliers, Distributors, Emerging Companies, Research Professionals and End-users
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research & Media features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.